Meeder Asset Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Meeder Asset Management’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-696	Closed	-$4K	–	2598
2019 Q4	$4K	Hold	696	–	–	﹤0.01%	1876
2019 Q3	$10K	Buy	696 +386	+125%	+$6.36K	﹤0.01%	1554
2019 Q2	$5K	Sell	310 -295	-49%	-$7.9K	﹤0.01%	1687
2019 Q1	$25K	Sell	605 -55	-8%	-$2.32K	﹤0.01%	1032
2018 Q4	$27K	Buy	660 +86	+15%	+$3.87K	﹤0.01%	984
2018 Q3	$28K	Buy	574 +539	+1,540%	+$27K	﹤0.01%	946
2018 Q2	$1.64K	Buy	+35	New	+$1.94K	﹤0.01%	1442

Other funds holding FSTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

Exane Derivatives Paris, France $174M AUM 7.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCA

Private Capital Advisors Darien, Connecticut $1.14B AUM 48.66% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Meeder Asset Management's FSTX Position: Q1 2020 in Review

Meeder Asset Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2020, closing a stake of 696 shares — an estimated $4K sold.

Meeder Asset Management first reported a position in FSTX in Q2 2018 and held it in 7 quarters. The position peaked at $28K in Q3 2018. 28 funds tracked by Wall St. Rank hold FSTX as of Q1 2020.

Meeder Asset Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Meeder Asset Management sold 696 F-star Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $4K.
Meeder Asset Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2018 and held it in 7 quarters.
Meeder Asset Management's F-star Therapeutics, Inc. Common Stock position peaked at $28K in Q3 2018.
28 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Meeder Asset Management's 13F filing for Q1 2020, filed 15 May 2020.